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Abstract
Background
Several countries or regions within countries have an effective national asthma strategy
resulting in reduction of the large burden of asthma to individuals and society. There has
been no systematic appraisal of the extent of national asthma strategies in the world.
Methods
The Global Asthma Network (GAN) undertook an email survey of 276 principal investigators
of GAN centres in 120 countries, in 2013-2014. One of the questions was:
asthma strategy been developed in your country for the next five years? For children? For
.
Results
Investigators in 112 (93.3%) countries answered this question. Of these, 26 (23.2%)
reported having a national asthma strategy for children and 24 (21.4%) for adults; 22
(19.6%) countries had a strategy for both children and adults; 28 (25%) had a strategy for at
least one age group. In countries with high prevalence of current wheeze strategies were
significantly more common than in low prevalence countries (11/13 (85%) and 7/31 (22.6%)
respectively, p<0·001).
Interpretation
In 25% countries a national asthma strategy was reported. A large reduction in the global
burden of asthma could be potentially achieved if more countries had an effective asthma
strategy.
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Introduction
Asthma is a common chronic disease affecting an estimated 241 million children and adults
in the world according to the estimates of the Global Burden of Disease 2013 (1), which
also . estimated that asthma was the 15th highest ranked cause of Years Lived with
Disability (1). Many people with asthma are unnecessarily disabled, because they are not
receiving optimal asthma management (2). In 2013, it was estimated that about 22 million
disability-adjusted life years are lost because of asthma (3). The International Study of
Asthma and Allergies in Childhood (ISAAC) found that the historical view of asthma being a
disease of high-income countries (HICs) no longer holds: most people affected are in low-
and middle-income countries (LMICs), and asthma prevalence is estimated to be increasing
fastest in those countries (4)
To reduce the burden of asthma, several HICs and LMICs have developed an asthma
strategy (or an asthma programme which is the terminology used by some countries) at a
national or regional level which have resulted in rapid reduction of the ill-effects of asthma
(5). The strategies or programmes are formalised with political engagement and
commitment. Implementation of such strategies includes relatively simple measures which
are consistently applied in the relevant population, to improve early detection of asthma and
provide access to effective anti-inflammatory treatment. Extension of this approach to other
countries or regions within countries could be of great potential benefit to reducing the
burden of asthma in the world.
The first comprehensive national asthma strategy was developed in Finland in 1994 and has
served as a model for other countries. They developed and called it a comprehensive
nationwide Asthma Programme and over the next decade this lessened the burden of
asthma on individuals and society and more than halved the total asthma costs (healthcare,
drugs, disability, and productivity loss) (6, 7) and these benefits have continued (8). This
model was followed several years later by several other national strategies within the
European Union (9) including France (10), Portugal (11), and Spain (12). In other places,
independent approaches have been used with improved outcomes, including Australia (13),
the city of Salvador, Brazil (14), Canada (15), Costa Rica (16), Singapore (17), Tonga (18)
and Turkey (19).
However, there are few reports of such strategies, suggesting that in many countries there is
no strategy or it has not been implemented. However there has been no systematic
appraisal of the numbers of countries in the world which have a national asthma strategy.
The Global Asthma Network (GAN) was established in 2012, a collaboration between
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individuals from ISAAC and the International Union Against Tuberculosis and Lung Disease
(The Union). Its goals are to improve asthma care globally, with a focus on low- and middle-
income countries (20), through enhanced surveillance, research collaboration, capacity
building and access to quality-assured essential medicines. Given the large number of
centres and countries involved with GAN, it was well placed to undertake such a survey.
Based on the low number of national asthma strategies reported in the literature, our
hypothesis was that most countries in the world do not have a national asthma strategy.
survey to be undertaken to answer a question about whether a country had a national
asthma strategy for children and adults.
Materials and Methods
A cross-sectional survey of GAN centres was carried out between April 2013 and July 2014.
A GAN centre was one where an Expression of Interest form had been submitted to the
GAN Global Centre (Auckland). The survey was by email survey and was sent to each
GAN principal investigators in 276 centres in 120 countries; 46 were HICs and 74 LMICs,
defined by the criteria used by the World Bank for the period 1 July 2013 - 30 June 2014
(21).
The survey form had eight questions, the last one of which was
strategy been developed in your country for the next five years? For children?
Know), F Know). The former seven questions were about national
asthma management guidelines in their country (not included in these analyses).
Where conflicting answers were given by two or more investigators from different centres
within a country, the GAN Global Centre staff entered into a discussion via email with the
centre investigators until agreement between them was reached.
Country findings were compared with the prevalence of asthma symptoms in 13-14 year olds
in countries where this had been estimated in ISAAC Phase Three (22). Countries were
categorised as high prevalence if the prevalence of current wheeze was >20%, and low
prevalence if the prevalence of current wheeze was <10%. The relationship of national
asthma strategies to changes in country prevalence of asthma symptoms in 13-14 year olds
in countries where this had been estimated in ISAAC Phase Three (4) was also examined.
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The data were entered into an excel spreadsheet and checked for apparent inconsistencies
which were reconciled if appropriate. Simple descriptive analyses were undertaken. The Chi-
Squared test was used to compare responses about strategies between LMICs and HICs,
(23).
Results
Of the 276 centre principal investigators in 120 countries, 213 (77.2%) investigators in 112
(93.3%) countries completed the national asthma strategy question. There were no
responses from any investigators in eight countries who were approached: three HICs and
five LMICs.
Conflicting answers were obtained from two or more centres in 16 countries, and agreement
was subsequently reached. Of the 112 countries, 43 (38.4%) were HICs including 48.3% of
69 (61.6%) were LMICs including 48.2
(Table).
Of those 112 countries where the national asthma strategy questions were answered for
seven in HICs and five in LMICs. For adults, 16 reported
, 11 in HICs and five in LMICs.
Of the 112 countries, 26 (23.2%) reported a national asthma strategy for children, 24
(21.4%) reported a national asthma strategy for adults, and 22 (19.6%) countries had
strategies for both children and adults. Twenty-eight (25%) had a national asthma strategy
for at least one age group. These are illustrated in the Figure.
Of the 28 countries who reported a national asthma strategy for at least one age group 15
(53.6%) were HICs and 13 (46.4%) LMICs. Strategies were reported in 15/43 (34.9%) HICs
and 13/69 (18.8%) LMICs; these differences were not significant p=0·057.
In 81/112 (72%) countries the prevalence of asthma symptoms had been estimated in
ISAAC. Any national asthma strategy was significantly more common in countries with high
prevalence of current wheeze (>20%) than low prevalence (<10%): 11/13 (85%) and 7/31
(22.6%) respectively, p<0·001, with the remaining 37 countries having prevalence 10-20%.
Of the 49 countries in whom time-trends in the prevalence of asthma symptoms had been
estimated in ISAAC, any national asthma strategy was equally common in those whose
prevalence rose (11/30) and in those in whom it fell (6/19) p=0·72.
Discussion
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In this email confirm our
hypothesis that most countries in the world do not have a national asthma strategy; only
about one in four countries reported that they had a national asthma strategy. Of potential
concern was that the proportion of LMICs with a strategy was lower than HICs, although this
was not statistically significant.
About three in four countries surveyed by GAN had the prevalence of asthma symptoms
measured in ISAAC, and of these, having a national asthma strategy was significantly more
common in countries with high prevalence compared with low prevalence of current wheeze.
While on the face of it this seems logical more asthma symptoms, more concern to take
action to address the issue - there are three caveats. Firstly, many of the countries with a
low prevalence of asthma symptoms and no national asthma strategy have very large
populations; for example Brazil, China, Indonesia, Mexico, Philippines each of which has
>100 million people and is among the top 12 most populous countries in the world in 2015
(24). Small improvements in the management and outcomes for people with asthma in each
of these countries would have a relatively big impact on the global numbers of people
burdened by asthma. Secondly, in this survey one in four countries had not measured their
asthma prevalence, which illustrates either their lack of interest in asthma or perhaps they
had experienced difficulties engaging in world-wide epidemiological studies. Thirdly, the
ISAAC data is already 13 years old (2002-3) and thus not coincident with this survey, so the
interpretation needs caution.
This is a very large study, a high response rate of 93% was achieved, data was reported
from 112 countries
LMICs. The response rate was high because of the close relationship between the GAN
Global Centre and GAN Principal Investigators.
The recommended components of a successful national asthma strategy include:
government commitment, policies and legislation (e.g. tobacco reduction), management by
the health ministry, funding and capacity building, registry of outcome data before and after
implementation (prevalence, severity, asthma control, hospitalisations, mortality), asthma
management guidelines adjusted for the country, access to medical care and quality-
assured, affordable, essential asthma medicines available for everyone with asthma,
education of the public, continued education of health professionals, economic analyses,
process and outcome evaluation, follow-up programmes, and continued asthma research (5,
9).
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There may be differe
. National asthma management
guidelines alone should not be considered a national asthma strategy or programme,
although they form an essential part. In this particular survey national asthma management
guidelines alone were unlikely to be confused with strategy, because they were asked about
in the preceding seven questions in the survey. However, the survey is likely to have missed
asthma strategies which were not country-wide; these would be more likely in a very large
country like Brazil or China. Additionally, some national asthma programmes may not have
strategies for the purpose of this survey.
In the review of national and regional asthma strategies in Europe (9), a systematic search
of the English literature in 2014 found only eight published national and regional asthma
strategies in European Union countries: Finland (7), France, Ireland, Italy, The Netherlands,
Lodz area of Poland, whole of Poland and Portugal (11), with only three strategies having
been evaluated (Finland, Poland, Portugal). Outside the European Union, asthma strategies
have been identified from only eight other countries (13-19, 25).
There are likely to be many reasons for the low level of publication of national asthma
strategies where they exist, including poor preparation with insufficient documentation,
dissemination, implementation or evaluation, lack of appropriate training of primary health
care professionals in diagnosis and treatment, poor access to quality assured, essential
asthma medicines, poor outcomes, unable to prepare an article for publication in English,
and publication bias. The absence of a national asthma strategy may reflect that asthma is
not recognised as a serious public health problem, a lack of asthma prevalence, severity and
mortality data, a lack of government prioritisation of asthma among other non-communicable
diseases, lack of national health coordination, and/or a lack of government commitment to
improving national health issues.
Not all national asthma strategies have been successful. Selroos and others have suggested
that good results can also be achieved without a formal national asthma strategy, as long as
evidence-based management guidelines are implemented and widely used (9). This is
happening, for example, in Sweden, where recommendations (in Swedish) for diagnosis and
treatment have been issued and updated by the National Board of Health and Welfare (26).
The Swedish Asthma and Allergy Foundation has recently issued a comprehensive national
strategy document. It has been estimated that global asthma deaths (all ages) reduced from
504,300 in 1990 to 489,000 in 2013 (27), but many countries do not report asthma deaths
separately (28). In Europe asthma mortality decreased from 6441 to 1164 cases (82%) from
1990-2012 (29).
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In 2009, a group of experts in asthma care, the Advancing Asthma Care Network, reviewed
asthma projects and strategies in Argentina, Australia, Brazil, China, Japan, Mexico, the
Philippines, Russia, South Africa, and Turkey (30). All successful asthma strategies
improved early diagnosis and the introduction of first-line treatment with anti-inflammatory
medication, improved long-term disease control nationally, introduced simple means for
guided self-management to proactively prevent exacerbations/attacks, and had effective
education and networking with general practitioners, nurses and pharmacists. A systematic
approach was recommended, aiming to motivate and organise, and improvements which
could be achieved with relatively simple means. When multidisciplinary actions are being
planned, all the main stakeholders should be represented.
A more limited approach to improving asthma outcomes has been used successfully in pilot
projects in LMICs, using standard case management encompasses
diagnosis of asthma, standardisation of treatment according to severity based on asthma
guidelines, and patient education, coupled with a simple system for monitoring patient
outcomes. Appropriate training of health care workers and availability of essential asthma
medicines are key to the effectiveness of standard case management. (31). Pilot studies in
2007-8 of the feasibility and effects of standard case management were applied in Benin
(32), Haiyuan County, Anhui Province, China (33), and Sudan (34) reduced hospitalisations
in those completing the study. In El Salvador 2005-2010 (35), by using Practical Approach to
Lung Health and essential asthma medicines free of charge, the number of patients being
referred from primary to secondary or tertiary level dropped by 60%, with greater
convenience for patients, and savings for health services.
Political engagement, leadership and commitment are key components for developing an
effective national asthma strategy, and these are challenging and may not be easily
achieved. The literature supports the view that programmes (strategies) are more likely to be
successful where this has occurred. The political organisation and health leadership in a
country would undoubtedly influence the chance of success, as would co-ordinated access
to affordable, quality-assured, essential asthma medicines. Identifying a political champion is
a critical factor, and may be easier in some localities than others. In 2010 the Global
Initiative for Asthma (GINA) launched a challenge to countries to reduce hospitalisations by
50% over 5 years (36) but the results have been modest. The motivation to tackle the
asthma burden is not always self-evident, e.g. in places where private health-care dominates
and hospitals compete.
In this survey we asked only about national asthma strategies, not local or regional
strategies. We know that there have been successful strategies in cities such as Salvador,
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Brazil (14); however these would not have been identified in our survey. Strategies at a sub-
national level may be the only feasible approach in some very large and populous countries
such as Brazil and China; in such cases, coverage of the whole nation by harmonised sub-
national strategies would be sought.
The survey asked about national asthma strategies for children separately from adults. Most
who reported strategies had them for both age groups. The reasons why there would be
separate strategies may include different approaches between children and adults, as often
happens with national asthma management guidelines. Or there may have been
ascertainment bias, with child health professionals not being aware that an asthma strategy
had been developed for adults and vice versa.
A successful strategy is not expected to affect prevalence and incidence as we do not have
effective interventions for these (20). However reduction in disease severity and improved
control may be impressive. In Finland in early 1990s, 20% of patients were estimated to
have uncontrolled (severe) asthma compared to 10% in 2001 and 4% in 2010 (7, 37). If the
gains of the Finnish study were replicated by having effective national asthma strategies
throughout the world, then the number of emergency visits would be estimated to fall by 24%
in adults and 61% in children, hospital days would fall by about 54%, significant disability
would decrease by about 76%, costs per patient per year would fall by 36%, and deaths by
31%. Even if half these gains were achieved, there would be a large reduction of the burden
of asthma in the world. Implementation of a national strategy is an appropriate way to
address asthma, where the disability numbers and costs are disproportionately high, in
contrast with the relatively high mortality found with other non-communicable diseases (20).
We recommend that health authorities along with governments in all countries should
develop national asthma strategies with associated national action plans to improve early
detection of asthma and subsequently improve asthma management and reduce costs (5).
Such strategies should be evaluated, reported, and published. The problems to be
addressed may be different in HICs compared to LMICs, and the solutions need to be
tailored according to local needs, resources and organisation.
Knowledge of asthma prevalence and severity and changes over time is fundamental to
understanding the burden of asthma within each country and thus leading to the
development of a national asthma strategy. This can be achieved using the methodology
developed by ISAAC (38, 39) and continued (expanded to include adults) under GAN (40).
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Table. Responses to national asthma strategy questions by country, age group and
country income.
Table (if other format than MS Word)


* LMIC = Low or Medium Income Country (by World Bank assessment).
#HIC = High Income Country (by World Bank assessment).
Figure
